Riximyo
Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
Fuljett ta 'informazzjoni
(PIL)
21-12-2023
Karatteristiċi tal-prodott
(SPC)
21-12-2023
Rapport ta 'Valutazzjoni Pubblika
(PAR)
15-06-2021
Ingredjent attiv:
rituximab
Disponibbli minn:
Sandoz GmbH
Kodiċi ATC:
L01FA01
INN (Isem Internazzjonali):
rituximab
Grupp terapewtiku:
Antineoplastic agents
Żona terapewtika:
Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis; Wegener Granulomatosis
Indikazzjonijiet terapewtiċi:
Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).
Sommarju tal-prodott:
Revision: 14
L-istatus ta 'awtorizzazzjoni:
Authorised
Data ta 'l-awtorizzazzjoni:
2017-06-15
Fuljett ta 'informazzjoni
71
B. PACKAGE LEAFLET
72
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
RIXIMYO 100 MG CONCENTRATE FOR SOLUTION FOR INFUSION
RIXIMYO 500 MG CONCENTRATE FOR SOLUTION FOR INFUSION
rituximab
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor, pharmacist or
nurse.
•
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Riximyo is and what it is used for
2.
What you need to know before you are given Riximyo
3.
How Riximyo is given
4.
Possible side effects
5.
How to store Riximyo
6.
Contents of the pack and other information
1.
WHAT RIXIMYO IS AND WHAT IT IS USED FOR
WHAT RIXIMYO IS
Riximyo contains the active substance “rituximab”. This is a type
of protein called a “monoclonal
antibody”. It sticks to the surface of a type of white blood cell
called “B-Lymphocyte”. When
rituximab sticks to the surface of this cell, the cell dies.
WHAT RIXIMYO IS USED FOR
Riximyo may be used for the treatment of several different conditions
in adults and children. Your
doctor may prescribe Riximyo for the treatment of:
A)
NON-HODGKIN’S LYMPHOMA
This is a disease of the lymph tissue (part of the immune system) that
affects a type of white blood cell
called B-Lymphocytes.
In adults Riximyo can be given alone or with other medicines called
“chemotherapy”.
In adult patients where the treatment is working, Riximyo may be used
as a maintenance treatment for
2 years after completing the initial treatment.
In children and adolescents, rituximab is given in combination with
“chemotherapy”.
B)
CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
CLL is the most common form of adult leukaemia. CLL affects a
particular lymphocyte, the B cell,
which originates from the bone marrow and develops in the lymph nodes.
Patients with CLL have
Aqra d-dokument sħiħ
Karatteristiċi tal-prodott
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Riximyo 100 mg concentrate for solution for infusion
Riximyo 500 mg concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Riximyo 100 mg concentrate for solution for infusion
Each mL contains 10 mg of rituximab.
Each 10 mL vial contains 100 mg of rituximab.
Riximyo 500 mg concentrate for solution for infusion
Each mL contains 10 mg of rituximab.
Each 50 mL vial contains 500 mg of rituximab.
Rituximab is a genetically engineered chimeric mouse/human monoclonal
antibody representing a
glycosylated immunoglobulin with human IgG1 constant regions and
murine light-chain and
heavy-chain variable region sequences. The antibody is produced by
mammalian (Chinese hamster
ovary) cell suspension culture and purified by affinity chromatography
and ion exchange, including
specific viral inactivation and removal procedures.
Excipient with known effect
Each 10 mL vial contains 2.3 mmol (52.6 mg) sodium.
Each 50 mL vial contains 11.5 mmol (263.2 mg) sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion (sterile concentrate).
Clear, colourless to slightly yellowish liquid with pH of 6.3 – 6.7
and osmolality of ≥ 240 mOsm/kg.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Riximyo is indicated in adults for the following indications:
Non-Hodgkin’s lymphoma (NHL)
Riximyo is indicated for the treatment of previously untreated adult
patients with stage III-IV
follicular lymphoma in combination with chemotherapy.
Riximyo maintenance therapy is indicated for the treatment of adult
follicular lymphoma patients
responding to induction therapy.
Riximyo monotherapy is indicated for treatment of adult patients with
stage III-IV follicular
lymphoma who are chemoresistant or are in their second or subsequent
relapse after chemotherapy.
3
Riximyo is indicated for the treatment of adult patients with CD20
positive diffuse large B cell non-
Hodgkin’s lymphoma in co
Aqra d-dokument sħiħ
